Scarica l'app Stockscreener
58.96
6.11%
-3.84
Dopo l'orario di chiusura:
59.25
0.29
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.80
Aprire:
$62.94
Volume 24 ore:
2.19M
Relative Volume:
1.02
Capitalizzazione di mercato:
$7.05B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-11.21
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-2.24%
1M Prestazione:
+18.49%
6M Prestazione:
+50.60%
1 anno Prestazione:
+6.66%
Intervallo 1D:
$58.40
$63.58
Intervallo di 1 settimana:
$58.40
$63.86
Portata 52W:
$29.31
$63.86
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
58.96 | 7.30B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
ROSEN, A LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK - GlobeNewswire Inc.
Cytokinetics (CYTK) CEO Blum sells $300k in shares - Investing.com India
Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire
Class Action Filed Against Cytokinetics, Incorporated (CYTK) - GlobeNewswire Inc.
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CYTK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cytokinetics, Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, - GlobeNewswire
Lost Money on Cytokinetics, Incorporated (CYTK)? Contact Levi & Korsinsky to Join Class Action Before November 17, 2025 - Newsfile
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
Should I hold or sell Cytokinetics Incorporated stock in 20252025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress
Cytokinetics stock hits 52-week high at 61.48 USD By Investing.com - Investing.com Nigeria
Cytokinetics stock hits 52-week high at 61.48 USD - Investing.com
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before ... - Caledonian Record
Recover Investment Losses: Class Action Initiated Against Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming DeadlinesCYTK - PR Newswire
Is Cytokinetics Incorporated forming a bottoming base2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Cytokinetics Incorporated2025 Performance Recap & High Conviction Investment Ideas - newser.com
Aberdeen Group plc Buys 320,508 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
Cytokinetics, Incorporated $CYTK Stake Increased by Mirae Asset Global Investments Co. Ltd. - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages - GlobeNewswire
Shareholders of Cytokinetics, Incorporated (CYTK): Protect Your Rights Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class ActionCYTK - PR Newswire
State of Alaska Department of Revenue Decreases Stake in Cytokinetics, Incorporated $CYTK - Defense World
Weiss Ratings Reiterates "Sell (D-)" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCYTK - Eastern Progress
Cytokinetics, Inc. Hits New 52-Week High at USD 61.42 - Markets Mojo
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors - GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - GuruFocus
How Cytokinetics Incorporated stock benefits from tech adoptionTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Top chart patterns to watch in Cytokinetics IncorporatedWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Cytokinetics, Inc. Hits New 52-Week High at $61.00 - Markets Mojo
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire
Malik, Cytokinetics evp, sells $121k in shares - Investing.com
Key facts: Pomerantz LLP filed a class action lawsuit against Cytokinetics on October 6-7, 2025, alleging securities fraud. Investors can apply to be Lead Plaintiff until November 17, 2025. - TradingView
December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - Morningstar
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 07 '25 |
Sale |
60.56 |
2,000 |
121,120 |
140,610 |
| Kaye Edward M. MD | Director |
Oct 06 '25 |
Sale |
60.00 |
6,757 |
405,420 |
9,778 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):